Glenmark launches anesthesia reversing agent sugammadex in US
NiveshIQ
NSE: GLENMARK · Pharma
Glenmark Pharmaceuticals Ltd.
₹2,261.70▲ ₹77.10 (+3.53%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on GLENMARK. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Limited is a leading Indian pharmaceutical company that develops, manufactures, and sells generics, specialty medicines, and over-the-counter (OTC) pharmaceutical products globally. The company operates in key therapeutic areas such as dermatology, respiratory, oncology, and cardiology, with a diverse product portfolio that includes complex injectables, biologics, oral solids, liquids, and topical products. Glenmark's product pipeline includes several promising candidates, including ISB 2001, a CD38 x BCMA x CD3 T cell engager in Phase 1 clinical trial for relapsed/refractory multiple myeloma. The company has reported strong financials, with revenue of ₹16,510 Cr and net income of ₹1,065 Cr. Glenmark's competitive position is strengthened by its global presence, di
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹11,813 Cr -9.10% | ₹13,322 Cr +12.80% | ₹16,983 Cr +27.50% |
| EBITDA Margin | 10.11% | 18.50% | 29.64% |
| Net Profit | -480.40% | ₹1,420 Cr | ₹1,362 Cr -4.10% |
| EPS | ₹-53.21 | – | ₹48.26 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Glenmark Launches Generic Sugammadex Injection in US, Expands Hospital Injectables Portfolio
Glenmark launches generic Sugammadex injection in US market
🔒
+ 3 more stories about Glenmark Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹3, 771 Cr, PAT ₹301 Cr, EPS ₹10.68, EBITDA margin 25.2%. Growth context: revenue QoQ -3.3%, PAT QoQ -25.2%. Street verdict: miss, revenue surprise +10.2%, PAT surprise -37.4%.
Product launches, approvals, and therapy-mix improvement, coupled with R&D investments and technology initiatives, are p...
Glenmark's FY26 performance was marked by revenue of ₹16, 983 Cr, PAT of ₹1, 362 Cr, and EBITDA margin of 29.6%, with EP...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for GLENMARK
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track GLENMARK alongside your other holdings
Unlock full GLENMARK research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Glenmark Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Glenmark Pharmaceuticals Ltd. (GLENMARK) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Glenmark Pharmaceuticals Ltd.?
Glenmark Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹6,494,287.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.